T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration.
Alginate
Chitosan nanoparticles
Tuberculosis
Vaccine
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
24
02
2021
revised:
11
06
2021
accepted:
26
06
2021
pubmed:
13
7
2021
medline:
10
8
2021
entrez:
12
7
2021
Statut:
ppublish
Résumé
Tuberculosis, a cost and life threatening disease, was being subjected for improving vaccine strategies beyond BCG. Thus, a novel particulate delivery system using alginate-coated chitosan nanoparticles including PPE17 protein and CpG were administered through intranasal (IN) and subcutaneous (SC) routes. The encapsulated nanoparticles were first characterized for size, surface charge, encapsulation efficiency and in vitro release of PPE17 antigen. The nanoparticles were then administered intranasal and subcutaneously to evaluate the induction of systemic and/or mucosal immune responses in mice. According to our result, the mean size of nanoparticles was measured about 427 nm, and exhibited a negative zeta potential of -37 mV. Following subcutaneous and intranasal administration, the results from cytokines assay showed that an increasing in the level of IFN-γ, and adversely a decrease in the level of IL-4 (presumptive Th1 biased immune response) was happened and also a notable elicitation in IL-17 cytokine was observed. In conclusion, our study demonstrated that alginate-coated chitosan nanoparticles showed to be an effective way to improve BCG efficiency as booster strategy for subcutaneous vaccine, and also can induce strong immune responses as prime strategy through intranasal vaccination.
Identifiants
pubmed: 34252419
pii: S0024-3205(21)00792-X
doi: 10.1016/j.lfs.2021.119806
pii:
doi:
Substances chimiques
Alginates
0
Antigens, Bacterial
0
Drug Carriers
0
Rv1168c protein, Mycobacterium tuberculosis
0
Tuberculosis Vaccines
0
Chitosan
9012-76-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119806Informations de copyright
Copyright © 2021. Published by Elsevier Inc.